MediWound (NASDAQ:MDWD) Share Price Passes Below 50 Day Moving Average – Should You Sell?

Shares of MediWound Ltd. (NASDAQ:MDWD) crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $17.29 and traded as low as $17.20. MediWound shares last traded at $17.70, with a volume of 21,690 shares trading hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their price target on shares of MediWound from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, November 27th.

MediWound Stock Performance

The company has a market capitalization of $190.91 million, a P/E ratio of -6.10 and a beta of 0.81. The firm’s fifty day moving average is $17.29 and its 200-day moving average is $17.46.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the prior year, the firm earned ($0.24) EPS. As a group, analysts expect that MediWound Ltd. will post -2.6 EPS for the current fiscal year.

Institutional Investors Weigh In On MediWound

A number of hedge funds and other institutional investors have recently bought and sold shares of MDWD. MetLife Investment Management LLC bought a new stake in MediWound during the third quarter worth about $89,000. Rhumbline Advisers bought a new stake in shares of MediWound in the 2nd quarter worth approximately $131,000. Barclays PLC raised its position in MediWound by 311.3% in the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock worth $202,000 after purchasing an additional 8,449 shares during the period. Point72 Asset Management L.P. bought a new position in shares of MediWound during the third quarter valued at about $212,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of MediWound in the second quarter worth about $342,000. Institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.